GENETIC MODIFICATION OF INTRAVASCULAR STENTS  by unknown
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 1 Special Communication 173 
number of cell types, including endothelial cells; however, smooth 
muscle cells do not express GTP:CH unless it is induced. This 
occurs in response to agonists, uch as prostacyclin, that elevate the 
levels of intracellular cyclic AME Therefore, treatment of pREP 9 
NOS 1II transfectants with a stable analog of PGI2, carbaprostacy- 
din, lead to production of NO (N02-), but this was not apparent in
cells transfected with the parent pREP 9 vector alone. 
The growth rates ofNOS III-transduced smooth muscle cells 
were significantly reduced as compared with control cells (pREP 9 
plasmid alone) in the presence of sepiapterin. This inhibition of 
growth was reversed significantly by inclusion of 400 gmol/L 
nitro-L-arginine in the culture medium. The presence of carba- 
prostacyclin elicited similar effects to those observed with sepiap- 
terin, and the growth inhibition of NOS llI-transduced cells was 
reversed by nitro-L-arginine. If smooth muscle cells were trans- 
fected with plasmid constructs encoding GTP:CH activity and 
then exposed to agonists (activators of protein kinase C, such as 
phorbol esters) that induce NOS (iNOS/NOS 1I) expression, they 
produced significant amounts of NO (N02-). This was not ob- 
served in cells transfected with control pREP 9 plasmid and exposed 
to the same NOS II-inducing agents. Expression of NOS II was 
confirmed ineach case byWestern blotting with a specific antibody. 
These findings are indicative of a possible added advantage to
the transduction fPGHS expression i smooth muscle ceils. The 
exposure of smooth muscle cells, transfected with NOS 1II, to PGI 2 
should result in the elevation of their intracellular levels of cyclic 
AMP sufficiently to induce GTP:CH activity and production of 
BH4. These events hould optimize production of NO by the 
transduced gene and thus obviate the necessity for the additional 
introduction of the GTP : CH gene into the smooth muscle cells to 
provide cofactor for NOS. 
The data demonstrate that proliferative hyperactivity, the first 
apparent drawback to the use of smooth muscle cells, in contrast to 
endothelial cells, as linings to cardiovascular p ostheses can be con- 
trolled by transduction fNOS expression. Growth rates were re- 
tarded by such genetic manipulation, but judicial use ofinhibitors 
ofNOS (nitro-L-arginine) allowed for high growth rates of trans- 
duced cells desirable during expansion of cell populations inculture 
to obtain sufficient cells for device-seeding purposes. The addi- 
tional beneficial effects of NO production, amely, passivation of 
platelets, remains to be demonstrated in experimental flow systems. 
The expression ofNOS III, which was maintained for several 
population doublings in the presence of G418, decreased rapidly 
with passage of cells in the absence of the selective pressure of 
antibiotic presence. It is intended that the transduced smooth 
muscle ceils will be seeded onto the internal surfaces of the LVAD 
before implantation athigh enough densities to form a confluent 
monolayer. Therefore, the number of population doublings that 
may occur after implantation i  the absence of the G418 selection 
pressure (resulting in the loss of NOS III expression) may be 
limited. Production of NO by the seeded cells will also limit the 
population doublings. Nonetheless, an additional strategy will be 
investigated in an attempt to maximize the advantages of having a 
cellular layer on the internal surfaces of LVADs. Smooth muscle 
cells will be transfected with VEGF (pREP 9 VEGF). Expression of 
VEGF will promote the growth of self-seeded, host endothelial 
cells over the smooth muscle cell layer. In LVAD pumps retrieved 
from patients, host-derived endothelial cells populate only those 
areas already covered with a pseudointima ofsmooth muscle-like 
cells. Therefore, host-derived endothelial cells may be capable of 
forming an endothelium-like covering. The source of these ndo- 
thelial cells remains controversial, however. 
In summary, smooth muscle cells will be engineered to behave 
as a pseudoendothelium during the initial phase of pump implan- 
tation. The production of NO, prostacyclin, and, if necessary, BH4 
will allow them to perform this function. At the same time, their 
production of a specific growth factor for endothelial cells (VEGF) 
will optimize their overgrowth by host endothelial cells. This will 
eventually ead to a cellular multllayer within the pump that mimics, 
to some extent, the structural organization ofa blood vessel wall. 
"The presencc of the host's own endothelial cells will hopefully 
maximize biocomparibllity and at the same time control platelet 
and smooth muscle activity. The engineered smooth muscle cells 
will provide atemporary pseudoendothelium and a substrata for the 
host to establish their own endothelial celi lining of the device. 
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GENETIC  MODIF ICAT ION OF 
INTRAVASCULAR STENTS 
The use of intravascular stents as an adjunct for percutaneous 
transluminal revascularization is limited principally by two factors: 
acute thrombosis in the period immediately after deployment and 
neointimal proliferation resulting in delayed stenosis. We have 
investigated the potential of microporous bioresorbable polymer 
stents formed from blends of poly(Lqactic acid) (PLLA) and 
poly(caprolactone) (PCL) to function both to provide mechanical 
support o the vessel wall (to overcome lastic recoil) and as 
reservoirs for the delivery of therapeutic molecules (to enhance 
healing). Tubular stents have been fabricated by a flotation/pre- 
cipitation technique from 75:25, 50 : 50 and 25 : 75 PLLA:PCL 
blends, respectively. Porosity and degradation rate increased, and 
mechanical strength decreased with increasing PCL content. He- 
lical stents have been produced from 100% ELLA, 75:25 and 
50 : 50 PLLA:PCL by a number of means, including, casting- and 
extrusion/winding. Complex structures inwhich a tubular sheath 
is deposited on a helical skeleton have also been generated. Using 
a two-stage solvent swelling, surface interpenetration technique 
polyethylene oxide (PEO) has been incorporated into these stents 
to improve hydrophilicity. This technique has improved water and 
viral stock absorption sevenfold, potenti~ly permitting these modi- 
fied stents to function as carriers for drug delivery. Stents fabricated 
from the 75 : 25 PLLA: PCL blends, when modified in this manner, 
retain tensile, and compressive strength, with spring coefficients 
sufficient o stabilize vessels against elastic recoil, vasoconstrictive 
and hemodynamic drag forces. Because of the potential for direct 
gene transfer into a vessel wall to ameliorate thrombosis and 
neointimal proliferation, we have investigated the capacity of these 
polymer stents to function in the delivery of recombinant adenovi- 
rus vectors. Virus stock absorbs into and elutes from these devices 
in an infectious form in vitro, with kinetics suitable for gene 
delivery. In particular, the dwell times for gene transfer are 
increased over those available by some balloon deposition tech- 
niques. Successful gene transfer and expression has been demon- 
strated after implantation of 75:25 PLLA:PCL, 4.0 mm OD 
polymer stents impregnated with a recombinant adenovirus carry- 
ing a nuclear localizing betagalactosidase reporter gene into rabbit 
carotid arteries. Infection of cells spanning the arterial wall was 
demonstrated. These studies uggest that surface-modified, biore- 
sorbable polymer stents may ultimately be useful adjunctive devices 
for percutaneous transluminal revascularization. 
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